Fosamax Litigation: Drug Safety, Failure-to-Warn Claims, and FDA Labeling Preemption

Fosamax Drug Safety, Failure-to-Warn, and FDA Labeling Overview

The Fosamax litigation remains one of the most closely examined prescription drug warning cases involving federal preemption. The dispute arose from claims that Merck did not provide an adequate warning about the risk of atypical femoral fractures associated with long-term Fosamax use. Over time, the case became an important reference point for courts evaluating when a drug manufacturer had sufficient scientific support to strengthen a warning and when federal law may block a state-law failure-to-warn claim.

What makes Fosamax especially important is that the case was not limited to whether plaintiffs alleged a serious injury. It turned on a more complex question: whether Merck could have changed its label sooner under FDA rules, or whether the agency would have rejected the warning at the time. This shifted the focus from general product safety arguments to a close review of regulatory submissions, FDA responses, and the timing of scientific evidence. For lawyers, Fosamax stands as a leading case on drug labeling and impossibility preemption. For general readers, it shows how prescription drug litigation can hinge on what a warning said, when it changed, and whether federal law allowed it to change earlier.

Key Legal Developments in the Fosamax Failure-to-Warn and FDA Labeling Litigation

May 25, 2011 - Fosamax Cases Were Centralized in Multidistrict Litigation

In 2011, the Judicial Panel on Multidistrict Litigation centralized Fosamax atypical femur fracture cases in the District of New Jersey. The panel consolidated actions alleging that Fosamax and alendronate sodium products were associated with atypical femur fractures and related injuries, allowing overlapping discovery and pretrial issues to be handled in a single court. This step created a unified forum for recurring disputes involving scientific evidence, labeling history, and federal preemption.

June 27, 2013 - District Court Ruled for Merck on Preemption Grounds

As the MDL progressed, the warning issue became central. Merck argued that the FDA would not have approved the stronger warning plaintiffs claimed was required under state law. Plaintiffs argued that the available evidence supported an earlier warning under FDA labeling rules. The district court granted summary judgment to Merck on preemption grounds, concluding that the regulatory record showed the FDA would not have approved the proposed warning at the time.

March 22, 2017 - Third Circuit Vacated the Preemption Ruling

The Third Circuit vacated the district court’s decision, allowing the plaintiffs’ claims to continue. The court held that the preemption analysis required closer examination of the regulatory record and clarified how courts should evaluate whether there is sufficient evidence that the FDA would have rejected a proposed warning.

May 20, 2019 - U.S. Supreme Court Issued Its Decision in Merck Sharp & Dohme Corp. v. Albrecht

The U.S. Supreme Court held that impossibility preemption in this context is a legal question for the judge, not the jury. The Court also explained that a manufacturer must show it fully informed the FDA of the basis for the warning and that the FDA, acting with the force of law, would not have approved the change. This decision provided a clearer framework for courts handling drug-label preemption disputes.

March 23, 2022 - District Court Again Found the Claims Preempted on Remand

On remand, the District of New Jersey again granted summary judgment to Merck. The court concluded that Merck had fully informed the FDA and that the agency’s regulatory record, including its prior communications, showed the FDA would not have approved the warning plaintiffs claimed was required.

September 20, 2024 - Third Circuit Reversed Again

In 2024, the Third Circuit again reversed. While the court agreed that Merck had presented substantial evidence of its communications with the FDA, it held that Merck had not shown the FDA would have rejected all warnings that could have satisfied state law. The ruling revived the plaintiffs’ claims and extended the litigation.

June 16, 2025 - U.S. Supreme Court Declined Further Review

Merck sought further review, but the U.S. Supreme Court denied certiorari on June 16, 2025. That left the Third Circuit’s 2024 ruling in place and marked another step in the long-running dispute over how impossibility preemption applies in pharmaceutical cases.

Expert Witness Roles in Fosamax Pharmaceutical Litigation and Drug Labeling Disputes

1. Regulatory Affairs Expert Witnesses

Regulatory affairs experts are commonly engaged in pharmaceutical litigation to evaluate FDA regulations, labeling requirements, and agency communications. In a case like Fosamax, their work would focus on whether the manufacturer could have used available FDA procedures to add or strengthen a warning and whether the regulatory record supports a preemption defense.

2. Pharmacology and Drug Safety Expert Witnesses

Pharmacology and drug safety experts are often consulted to assess how a medication works and whether reported adverse events, published studies, and safety signals supported concern at a particular time. In Fosamax-related litigation, this analysis helps frame whether a warning was scientifically supportable before it was added.

3. Medical Causation Expert Witnesses

Medical causation experts are typically used to evaluate whether a drug is capable of causing a claimed injury and whether it likely contributed to a specific patient’s condition. In Fosamax cases, this often involves reviewing medical records, fracture history, duration of use, and other risk factors to determine whether the injury aligns with reported atypical femoral fracture patterns.

4. Epidemiology Expert Witnesses

Epidemiology experts are often asked to evaluate population-level data and determine whether published studies show a meaningful association between a drug and a claimed injury. In Fosamax litigation, their analysis can be central to disputes over whether the available evidence reflected a confirmed risk or an emerging signal requiring further study.

5. Orthopedic Expert Witness

Orthopedic experts are commonly consulted in fracture-related litigation to evaluate the nature of the injury, bone health, treatment history, and fracture pattern. In atypical femoral fracture claims, their testimony can help distinguish these injuries from more typical fractures and assess whether the medical record supports the allegations.

Legal Insights for Lawyers Handling Pharmaceutical Drug Safety and Warning Label Cases

1. Preemption can control the outcome of the case.

Fosamax shows that a prescription drug case may turn less on general safety arguments and more on whether federal law allowed a stronger warning. When FDA communications and label history are central, preemption can become the decisive issue.

2. Timing is often the most difficult part of the warning analysis.

The case was not simply about whether atypical femoral fractures became associated with Fosamax. The key issue was when the available evidence became strong enough to support a warning under FDA standards.

3. FDA records can become core evidence.

Agency submissions, labeling history, and formal FDA responses are often central to summary judgment decisions. In Fosamax, these materials played a defining role in the outcome.

4. Scientific and regulatory issues are closely connected.

In pharmaceutical litigation, scientific evidence and regulatory standards often overlap. Fosamax shows how arguments about safety evidence and FDA decision-making can develop together.

5. Supreme Court guidance can change future litigation.

The 2019 decision established a framework that continues to influence how courts analyze impossibility preemption in drug-labeling cases.

Conclusion

Fosamax stands out because it required courts to work through a detailed regulatory record rather than resolve a simple dispute about injury and causation. What began as claims involving unusual thigh-bone fractures became a broader examination of warning language, FDA communications, and the limits on a manufacturer’s ability to update a label without prior approval.

The case shows that pharmaceutical litigation often depends on timing. It is not enough to show that a risk exists. The key question is whether the manufacturer had enough evidence at a specific point in time to justify a warning and whether the FDA would have allowed that change. In Fosamax, those questions changed the outcome at multiple stages of the litigation.